TERN Terns Pharmaceuticals
- 6.010
- -1.010-14.39%
- 6.200
- +0.190+3.16%
Terns Pharmaceuticals News
Optimistic Buy Rating for Terns Pharmaceuticals Amid Promising Clinical Progress and Solid Financial Footing
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)
Buy Rating Affirmed for Terns Pharmaceuticals Amid Robust Financials and Promising Pipeline Prospects
Terns Pharma Analyst Ratings
Hold Rating on Terns Pharmaceuticals Pending Clinical Trial Outcomes
Analysts Are Bullish on These Healthcare Stocks: Alphatec Holdings (ATEC), Terns Pharmaceuticals (TERN)
Terns Pharma Analyst Ratings
Market Outperform Rating for Terns Pharmaceuticals With a $15 Price Target Based on TERN-701's Strong Clinical Profile
Optimistic Buy Rating for Terns Pharmaceuticals Based on TERN-701 Market Potential and Strategy
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Buy Rating on Terns Pharmaceuticals Amid Promising Developments in Obesity Treatment Sector
Terns Pharma Analyst Ratings
Optimistic Buy Rating for Terns Pharmaceuticals Based on Strong Clinical Pipeline and Financial Stability
Terns Pharma Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
Optimistic Buy Rating for Terns Pharmaceuticals Amid Strong Financials and Promising Clinical Trials
Hold Rating on Terns Pharmaceuticals Amid Anticipation of Clinical Milestones for TERN-701 and TERN-601
Terns Pharma Analyst Ratings
Buy Rating Affirmed for Terns Pharmaceuticals Amid Positive Industry Outlook and Strategic Positioning
Analysis
Price Target
No Data
